Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has provided an update.
Qyuns Therapeutics Co., Ltd. announced a voluntary on-market share repurchase, indicating that the board believes the current share price undervalues the company’s worth. The repurchase of 549,800 ordinary shares, valued at approximately HK$11.07 million, aims to reinforce market confidence and enhance investment value, though future repurchases will depend on market conditions.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on developing therapeutic solutions and is listed on The Stock Exchange of Hong Kong Limited.
Average Trading Volume: 949,789
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.37B
For a thorough assessment of 2509 stock, go to TipRanks’ Stock Analysis page.